

## **Radiopharm Theranostics notifies end of Share Subscription Agreement and Share Purchase Agreement with Lind Partners**

Sydney, Australia – 2 July 2024 – **Radiopharm Theranostics Limited** (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, confirms that, as part of RAD's broader funding arrangements announced on 25 June 2024, it has notified Lind Global Fund II, LP (**Lind**) of the Company's intent to exercise its right to terminate the Share Subscription Agreement and Share Purchase Agreement between Radiopharm and Lind announced on 6 February 2024 effective immediately in accordance with the terms set out in that announcement.

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: rc@radiopharmtheranostics.com

Paul Hopper  
Executive Chairman  
E: paulhopper@lifescienceportfolio.com

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>